Reported data represents the observed association between use of insulin secretagogues preceding breast cancer diagnosis and GM-CSF, G-CSF and IL-7 profiles at the time of cancer diagnosis in women with diabetes mellitus (Table 1). This evidence concerns the gene CSF2 and breast carcinoma.